Monitoring and Management of Fibrodysplasia Ossificans Progressiva: Current Perspectives [Corrigendum]
Smilde BJ, Botman E, de Ruiter RD, et al. Orthop Res Rev. 2022;14:113–120. On page 118, Treatments in Development section, 2nd paragraph, 2nd sentence “The only drug in development for FOP in this medication class is Palovarotene, a retinoic acid-gamma (RAR-γ) antagonis...
| Hlavní autoři: | , , , , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Dove Medical Press
2022-05-01
|
| Edice: | Orthopedic Research and Reviews |
| On-line přístup: | https://www.dovepress.com/corrigendum-monitoring-and-management-of-fibrodysplasia-ossificans-pro-peer-reviewed-fulltext-article-ORR |